BioSpace News Archive

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced the pricing of its previously announced underwritten public offering of 4,237,288 shares of its common stock at a price to the public of $29.50 per share.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the investment banks Jefferies and Kempen have initiated analyst coverage of Sensorion.

OncoZenge AB, Moberg Pharma’s subsidiary, announced that the European Patent Office has granted patent 3 284 459 which protects BupiZenge®, currently in development for treatment of pain due to oral mucositis.

BioGeneration Ventures, a leading early-stage VC in European biopharma, announces the closing of BGV IV at €140 million.

RVO, an agency of the Dutch Ministry of Economic Affairs and Climate Policy, provides a loan of up to €5 million for the COVID-19 cohort clinical study

TransCon ™ C-Type Natriuretic Peptide (CNP), an investigational once-weekly long-acting prodrug of CNP, is ready for Phase 2 Clinical Trial in China

Product candidate taladegib inhibits chronic Hedgehog signaling pathway, an underlying mechanism behind Idiopathic Pulmonary Fibrosis (IPF)

Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately 42% Compared with 2019

Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Andrew Miller, Ph.D., chief operating officer and founder, will participate in a fireside chat at the ICR Conference 2021

Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 CIFFREO study, which will evaluate the efficacy and safety of investigational gene therapy candidate PF-06939926 in boys with Duchenne muscular dystrophy (DMD).